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AbstrAct
Purpose Crizotinib is a potent, orally administered 
tyrosine kinase inhibitor approved for the treatment of 
anaplastic lymphoma kinase (ALK)-positive advanced 
non-small-cell lung cancer (NSCLC). We report final 
results from PROFILE 1005, the largest clinical trial to 
date for an ALK inhibitor in ALK-positive NSCLC.
Patients and methods PROFILE 1005 (NCT00932451) 
was a multicenter, single-arm phase 2 trial of the 
efficacy, safety and tolerability of crizotinib (250 mg 
twice daily; 3 week continuous treatment cycles) in 
patients with ALK-positive NSCLC after failure of ≥1 
lines of systemic treatment for locally advanced/
metastatic disease. Patients’ tumour ALK status was 
initially determined by a central laboratory until a 
protocol amendment permitted enrolment of patients 
based on locally determined ALK status. Co-primary 
endpoints were objective response rate (ORR), 
evaluated using Response Evaluation Criteria in Solid 
Tumours V.1.1 and adverse events (AEs). Cancer-
specific patient-reported outcomes (PROs) were also 
assessed using the European Organisation for the 
Research and Treatment of Cancer QLQ-C30 and its 
lung cancer module QLQ-LC13.
Results 1069 patients were enrolled; 1066 received 
crizotinib. The as-treated population comprised 908 and 
158 patients, in whom tumour positive ALK-status was 
determined centrally (± locally) or locally only, respectively. 
At baseline, a majority of patients were <65 years (84%), 
66% were never smokers and 46% were Asian. Derived 
investigator-assessed ORR was 54% (95% CI 51 to 57) 
and 41% (95% CI 33 to 49) in the central-testing and 
local-testing subgroups, respectively. The most common 
treatment-related AEs in the overall population (any grade) 
were vision disorder (58%), nausea (51%), diarrhoea (47%) 
and vomiting (47%). PRO scores demonstrated clinically 
meaningful improvement in lung cancer symptoms and 
global quality of life.
Conclusion The efficacy, safety and PRO profiles of 
crizotinib in this cohort of 1066 patients with ALK-positive 
NSCLC are consistent with previous reports.
Trial registration number Phase 2 trial (NCT00932451); 
Results.
IntroductIon
The first-in-class anaplastic lymphoma 
kinase (ALK) inhibitor, crizotinib, is a potent, 
orally administered inhibitor of ALK, MET and 
ROS1 tyrosine kinases.1 The single-arm phase 
1 trial of crizotinib (PROFILE 1001) showed 
an objective response rate (ORR) of 61% 
in 143 patients with advanced ALK-positive 
Key questions
What is already known about this subject?
 ► Crizotinib is a first-in-class, oral, potent, 
small molecule tyrosine kinase inhibitor of anaplastic 
lymphoma kinase (ALK), ROS1 and c-MET, approved 
in several countries for the treatment of ALK-positive 
metastatic non-small-cell lung cancer (NSCLC).
What does this study adds?
 ► PROFILE 1005 is the largest study to date for any 
ALK inhibitor in ALK-positive  advanced NSCLC 
and provides further data from over 1000 patients 
supporting the clinical efficacy and safety profile of 
crizotinib  in patients with previously  treated ALK-
positive NSCLC.
How might this impact on clinical practice?
 ► The results of this study strengthen the evidence 
base for crizotinib as the standard of care for ALK-
positive NSCLC.
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NSCLC.2 Based on the results from the first 136 patients 
enrolled in the present study where an ORR of 51% was 
observed, crizotinib received accelerated approval in 2011 
by the US Food and Drug Administration (FDA) for the 
treatment of patients with locally advanced or metastatic 
NSCLC that is ALK positive,3 as detected by a FDA-ap-
proved test. A conditional approval in the EU for the 
treatment of adults with previously treated ALK-positive 
NSCLC was also received.4 The results of the randomised 
phase 3 PROFILE 1007 study demonstrating superiority 
of crizotinib to standard-of-care single-agent chemo-
therapy, in patients with previously treated ALK-positive 
NSCLC, supported conversion to full approval in the USA 
and the EU.5
The most common adverse events (AEs) associated 
with crizotinib in PROFILE 1007 included vision disor-
ders (most commonly visual impairment, photopsia or 
blurred vision), gastrointestinal effects (most commonly 
diarrhoea, nausea, vomiting or constipation) and 
elevated liver aminotransferases.5 Subsequently, in the 
first-line setting, significantly prolonged progression-free 
survival (PFS) was demonstrated for crizotinib compared 
with standard pemetrexed-plus-platinum chemotherapy 
in the PROFILE 1014 study in patients with previously 
untreated advanced ALK-positive NSCLC, with a similar 
safety profile observed to that seen in PROFILE 1007.6
Here, we report the final results of PROFILE 1005 
that enrolled 1066 patients treated with crizotinib. This 
large study expands knowledge of the incidence of toxic-
ities noted previously (eg, bradycardia, renal cysts) and 
permits improved characterisation of crizotinib.
Methods
Patients
In the original protocol, the study sample size was set at 
250 patients and considered to be adequate to estimate 
ORR and its 95% CI, in case the true ORR ranged from 
30% to 50%. Based on enrolment rate and the closure 
of PROFILE 1007 to enrollment in some countries, 
the sample size was initially increased to 400 patients, 
which was also considered adequate to detect AEs of 
low frequency. Subsequently, the sample size was further 
increased to 800 patients in order to better understand 
possible genetic associations with specific renal and 
hepatic AEs. The sample size was revised again to allow 
continued enrolment of patients from the chemotherapy 
arm of PROFILE 1007 and to allow enrolment of up to 
an additional 250 patients to meet country-specific regu-
latory requirements, giving a projected enrolment in the 
order of 1100 patients.
Eligible patients were aged ≥18 years with locally 
advanced or metastatic ALK-positive NSCLC that 
had progressed after one or more systemic treatment 
regimens. Initially, the ALK status of all tumours was 
determined by a central laboratory using break-apart 
fluorescence in situ hybridisation (FISH) (Abbott Molec-
ular, Des Plaines, Illinois, USA). In January 2011 (at which 
point 233 patients had been recruited), the protocol was 
amended to allow enrolment of patients whose tumours 
were determined to be ALK-positive at a local laboratory, 
with no requirement as to the specific test used and the 
cut-off defining ALK-positivity. Other inclusion criteria 
included an Eastern Cooperative Oncology Group 
performance status of 0–3, adequate bone marrow and 
organ function and resolution of all acute toxic effects of 
prior therapy or surgical procedures to grade ≤1 (except 
for alopecia). Patients with brain metastases were eligible 
if asymptomatic or if treated, neurologically stable for ≥2 
weeks. All patients provided written informed consent 
prior to screening.
Patients in the chemotherapy arm of PROFILE 1007 
were permitted to enrol in this study in order to receive 
crizotinib following independent radiology laboratory-de-
fined disease progression.
study design and treatment
This was an open-label, multinational, phase 2 clinical 
trial performed at 143 centres in 22 countries. The insti-
tutional review board or independent ethics committee 
at each participating centre approved the protocol, which 
complied with the International Ethical Guidelines for 
Biomedical Research Involving Human Subjects, Good 
Clinical Practice guidelines, the Declaration of Helsinki 
and local laws. The study began in January 2010 and the 
cut-off date for the final analysis reported here was 16 
March 2015.
Patients were to receive open-label crizotinib orally at 
a starting dose of 250 mg twice daily given on a contin-
uous daily dosing schedule until disease progression, 
clinical deterioration, unacceptable toxicity, withdrawal 
of patient consent or protocol non-compliance. Patients 
with progressive disease (PD) could continue treatment 
if the investigator considered them to be deriving clinical 
benefit. A treatment cycle was defined as 3 weeks.
study assessments and conduct
Radiographic tumour assessments were performed at 
screening, every 6 weeks for the first 10 cycles and there-
after, every 12 weeks. Antitumour efficacy was evaluated 
using Response Evaluation Criteria in Solid Tumours 
(RECIST) V.1.1. Brain and bone scans were performed at 
screening and, if necessary, at intervals of 6 (for brain) or 
12 (for bone) weeks. Safety assessments included moni-
toring AEs, vital signs, physical examinations, 12 lead 
ECGs, ophthalmological examinations and clinical labo-
ratory evaluations. AEs were reported and graded using 
National Cancer Institute Common Terminology Criteria 
for Adverse Events, V.4.0. Patient reported outcomes 
(PROs) of global quality of life (QOL), disease/treat-
ment-related symptoms of lung cancer and general 
health status were assessed using the European Organisa-
tion for the Research and Treatment of Cancer (EORTC) 
QLQ-C30 and QLQ-LC13 and the EuroQol-5D (EQ-5D) 
questionnaire. These PROs were scored according to 
the EORTC QLQ-C30 scoring manual and the EQ-5D 
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Table 1 Patient demographics and baseline disease characteristics (as-treated population)
Central ALK-testing subgroup 
(n=908)
Local ALK-testing subgroup
(n=158)
All patients
(n=1066)
Sex
  Male 393 (43) 72 (46) 465 (44)
  Female 515 (57) 86 (54) 601 (56)
Age (years), n (%)
  <65 years 777 (86) 117 (74) 894 (84)
  ≥65 years 131 (14) 41 (26) 172 (16)
  Median (range) 52.0 (19–84) 53.0 (21–84) 52.0 (19–84)
Race n (%)
  White 434 (48) 98 (62) 532 (50)
  Black 16 (2) 4 (3) 20 (2)
  Asian 442 (49) 53 (34) 495 (46)
  Japanese 67 (7) 14 (9) 81 (8)
  Korean 138 (15) 6 (4) 144 (14)
  Chinese 224 (25) 28 (18) 252 (24)
  Other Asian 13 (1) 5 (3) 18 (2)
  Other 16 (2) 3 (2) 19 (2)
Smoking classification, n (%)
  Never 612 (67) 90 (57) 702 (66)
  Former 259 (29) 62 (39) 321 (30)
  Current 37 (4) 6 (4) 43 (4)
Duration since histopathological diagnosis (years)
  Mean (range) 2.1 (0.0–13.7)* 1.8 (0.1–9.5) 2.1 (0.0–13.7)
Extent of disease, n (%)
  Locally advanced 77 (9) 9 (6) 86 (8)
  Metastatic 831 (92) 149 (94) 980 (92)
Histological classification, n (%)
  Adenocarcinoma 859 (95) 147 (93) 1006 (94)
  Squamous-cell carcinoma 22 (2) 4 (3) 26 (2)
  Large-cell carcinoma 7 (<1) 2 (1) 9 (<1)
  Other† 20 (2) 5 (3) 25 (2)
ECOG performance status, n (%)
  0 214 (24) 38 (24) 252 (24)
  1 541 (60) 94 (60) 635 (60)
  2 125 (14) 18 (11) 143 (13)
  3 28 (3) 8 (5) 36 (3)
Number of prior therapies for metastatic disease
  0 2 (<1) 0 2 (<1)
  1 231 (25) 67 (42) 298 (28)
  2 335 (37) 49 (31) 384 (36)
  ≥3 340 (37) 42 (27) 382 (36)
Data are n (%) unless otherwise indicated.
*Disease duration was not specified for one patient.
†Other classification includes adenosquamous carcinoma, sarcomatoid, mucoepidermoid, epidermoid, hepatoid carcinoma and other.
ALK, anaplastic lymphoma kinase; ECOG, Eastern Cooperative Oncology Group; EGFR, epidermal growth factor receptor; TKI, tyrosine 
kinase inhibitor.
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user guide. Visual symptoms were assessed on the Visual 
Symptom Assessment Questionnaire-ALK (VSAQ-ALK).
Analyses
The as-treated population included all enrolled patients 
treated with ≥1 dose of crizotinib. The response-evaluable 
population comprised all patients in the as-treated popu-
lation who had adequate baseline tumour assessments. 
The primary efficacy endpoint was ORR (percentage of 
patients with a confirmed complete or partial response) 
as per RECIST V.1.1, derived based on investigator assess-
ment, in the response-evaluable population. The derived 
best overall response (BOR) was based on the target 
lesion measurements, non-target lesion assessments and 
new lesion records provided by the investigator. Other 
efficacy endpoints included duration of tumour response 
and time to first tumour response (both assessed in the 
response-evaluable population), PFS and overall survival 
(OS; both assessed in the as-treated population). Effi-
cacy data were summarised both for patients in whom 
tumour ALK status was determined centrally (± locally) 
and those determined locally only (‘central’ and ‘local’ 
subgroups, respectively), although the study was not 
designed to compare efficacy in the two subgroups. 
ORRs in each subgroup were also summarised by base-
line characteristics. For each calculated ORR, two-sided 
95% exact CIs were provided. Time-to-event endpoints 
were analysed using the Kaplan-Meier method; two-sided 
95% CIs were provided for median PFS and OS. Safety 
data were summarised in the as-treated population and 
in subsets (gender, ≥65 vs <65 years, Asian vs non-Asian 
ethnicity). Based on previous experience with crizotinib, 
the following AEs of special interest were also summarised 
(including the following clustered terms, footnote #2 in 
table 3): elevated transaminases, hepatotoxicity, inter-
stitial lung disease (ILD, encompassing pneumonitis), 
ECG QT prolonged and renal cysts. Additional analyses 
of AEs of special interest also included time to first onset 
and duration of the adverse event. PRO endpoints were 
analysed in the PRO-evaluable population (all patients in 
the as-treated population who completed a baseline PRO 
assessment and one or more postbaseline PRO assess-
ments). For the change from baseline analyses of PRO 
scores, the change was considered statistically significantly 
different from 0 (at p<0.05) if the 95% CIs excluded 0. 
There were no adjustments for multiplicity testing.
results
Between January 2010 and September 2014, 1069 
patients were enrolled, 1066 received crizotinib, 908 had 
ALK-positive status determined centrally (± locally) and 
158 determined solely by local-testing (see table 1 in the 
online Supplementary file 1). In the local only subgroup, 
methods used to determine ALK status were FISH 
(n=124), PCR (n=26) or immunohistochemistry (IHC) 
(n=8). All treated patients had adequate baseline tumour 
assessment, and therefore the response-evaluable popula-
tion was the same as the as-treated population.
At baseline, patients’ median (range) age was 52.0 
years (19–84), a majority of patients (84%) were <65 
years old, 50% of patients were White, 46% were Asian 
and 66% were never smokers (table 1). The median dura-
tion of treatment was 45.6 weeks (95% CI 42.1 to 50.1). A 
total of 122 (11%) patients across both subgroups were 
still receiving crizotinib at the time of data cut-off. The 
reasons for permanent treatment discontinuation are 
shown in table 2 in the online Supplementary file 1. The 
most common reasons for permanent discontinuation 
were disease progression (31%) and deterioration of 
health status (27%). In the central and local only testing 
subgroups, 63% and 52% of patients with RECIST-defined 
PD continued crizotinib beyond PD (median duration, 
21.9 and 19.8 weeks, respectively).
efficacy
The ORR in the central-testing subgroup was 54% (95% 
CI 51 to 57) (table 2). ORR results by patient demo-
graphic and disease characteristics are also summarised 
in table 2. The ORR was 41% (95% CI 33 to 49), in the 
subgroup of 158 patients with positive local ALK testing 
only. For the 163 patients whose tumour samples had posi-
tive ALK status obtained locally and confirmed centrally, 
the ORR was 57% (95% CI 49 to 65), in line with the 
centrally tested group (ORR of 54%). The median PFS 
in the central-testing and local-testing subgroups was 8.4 
months (95% CI 7.1 to 9.7) and 6.9 months (95% CI 5.6 to 
9.4), respectively (figure 1A, table 2) and the median OS 
was 21.8 months (95% CI 19.4 to 24.0) and 16.9 months 
(95% CI 13.4 to 21.5), respectively (figure 1B, table 2). 
The PFS and OS by number of prior therapies are shown 
in table 3 in the online Supplementary file 1).
safety and tolerability
Treatment-related adverse events (TRAEs) occurred in 
96% of patients (table 3). The most common TRAEs 
(any grade) were vision disorder (58%), nausea (51%), 
diarrhoea (47%) and vomiting (47%). Other common 
events (in ≥30% patients) were oedema (38%), constipa-
tion (35%) and elevated transaminases (30%). The most 
common grade 3 or 4 TRAEs were neutropenia (13%) 
and elevated transaminases (8%).
TRAEs reported at a higher frequency (≥10 percentage 
points higher) in female patients than male patients were 
vision disorder, nausea, vomiting, oedema, neutropenia 
and dysgeusia. Oedema occurred at a higher frequency 
in patients aged ≥65 than <65 years. Constipation, neutro-
penia, elevated transaminases, leucopenia and decreased 
appetite were reported at a higher frequency among 
those of Asian than non-Asian ethnicity.
When looking at the TRAEs characterising the safety 
profile of crizotinib, the most frequently reported was 
vision disorder (58%; which includes visual impairment, 
photopsia, vision blurred, vitreous floaters, photophobia 
and diplopia). This was mild or moderate in the majority 
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Table 2 Efficacy results (as-treated population*)
 Parameter
Central ALK-testing (n=908) Local ALK-testing (n=158)
Result 95% CI Result 95% CI
BOR, n (%)
  CR 11 (1) – 1 (<1) –
  PR
  
480 (53) – 63 (40) –
  ORR, n (%)
  
491 (54) 51 to 57† 64 (41) 33 to 49†
Median DR, months 11.8 10.4 to 12.8‡ 9.5 6.9 to 15.2‡
DCR, n (%)
  At 6 weeks 742 (82) 79 to 84† 110 (70) 62 to 77†
  At 12 weeks 643 (71) 68 to 74† 97 (61) 53 to 69†
Median time to first tumour 
response, weeks
6.1 2.7 to 164§ 6.3 4.7 to 65.9§
Median PFS, months 8.4 7.1 to 9.7‡ 6.9 5.6 to 9.4‡
Survival probability, %
  At 6 months 82 79 to 84¶ 78 70 to 8§¶
  At 12 months 67 63 to 70¶ 62 54 to 60¶
Median OS, months 21.8 19.4 to 24.0‡ 16.9 13.4 to 21.5‡
ORR by patient characteristics*
Central ALK-testing (n=908) Local ALK-testing (n=158)
n/N** % 95% CI† n/N** % 95% CI†
Overall 491/908 54 51 to 57 64/158 41 33 to 49 
Number of prior therapies for metastatic disease
  0 2/2†† 100 16 to 100 0 – –
  1 126/231 55 48 to 67 27/67 40 29 to 53
  2 166/335 50 44 to 55 20/49 41 27 to 56
  ≥3 197/340 58 53 to 63 17/42 41 26 to 57
Sex
  Male 211/393 54 49 to 59 27/72 38 26 to 50
  Female 280/515 54 50 to 59 37/86 43 32 to 54
Age‡‡
  <65 years 424/777 55 51 to 58 49/117 42 33 to 51
  ≥65 years 67/131 51 42 to 60 15/41 37 22 to 53
Race
  Non-Asian
   White 215/434 50 45 to 54 36/98 37 27 to 47
   Black 9/16 56 30 to 80 1/4 25 0.6 to 81
  Asian
   Japanese 37/67 55 43 to 67 9/14 64 35 to 87
   Korean 105/138 76 68 to 83 3/6 50 12 to 88
   Chinese 111/224 50 43 to 56 9/28 32 16 to 52
   Other Asian 7/13 54 25 to 81 5/5 100 48 to 100
   Other 7/16 44 20 to 70 1/3 33 0.8 to 91
ECOG PS§
  0 127/214 59 52 to 66 15/38 40 24 to 57
Continued
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of patients (grade ≤2: 58%), with a median (range) time to 
first onset of 7 (1–1363) days after commencing treatment. 
Most (≥65%) of the patients who reported experiencing 
a visual symptom in the first 30 cycles, assessed on the 
VSAQ-ALK, indicated that they had no or minimal impact 
(scores 0–3 of 10) on daily activities. A treatment-related 
grade 4 optic atrophy event was reported in one patient.7 
Nausea, diarrhoea and vomiting were predominantly 
mild to moderate in severity (table 3), with a median 
(range) time to first onset of 3 (1–1022), 13 (1–1383) and 
2 (1–1055) days, respectively.
Treatment-related elevated transaminases of any 
grade occurred in 30% of patients, with a median time 
to first onset of 23 (1–1331) days. A total of 286/1066 
(27%) patients had elevations in alanine aminotrans-
ferase (ALT) and 4/1066 (0.4%) had elevations in total 
bilirubin levels. Drug-induced liver injury meeting Hy’s 
law criteria (elevated transaminases and total bilirubin 
levels without evidence of cholestasis) developed in eight 
patients, including two cases of hepatotoxicity events with 
a fatal outcome. Twenty-five patients (2%) experienced 
treatment-related ILD, with a median time to onset of 
78 (6–1028) days; 10 patients (1%) had treatment-re-
lated ILD of grade 3 severity or worse. Thirteen cases of 
treatment-related ILD, three of which were fatal, were 
associated with treatment discontinuation.
ECG QT prolongation was reported as a TRAE in 37 
patients (4%); 12 patients had events of grade 3 severity. 
Fifteen of 999 patients (2%) had corrected QT (QTc) 
using Fridericia’s correction (QTcF) of ≥500 ms and a 
maximum QTcF change from baseline of ≥60 ms was 
observed in 47/981 patients (5%). Seven patients (0.7%) 
had treatment-related syncope but whether associated 
with a change in QTc is not known. No patients perma-
nently discontinued crizotinib due to QT prolongation, 
although six and eight underwent dosing interrup-
tions and dose reductions, respectively. Bradycardia was 
reported as a TRAE for 11% of patients (mostly grade 1 or 
2 in severity). In 13% of patients, a pulse rate <50 beats/
min on treatment was noted.
Renal cysts considered treatment-related were reported 
for 30 patients (3%). Most cases were grade 1 or 2 
although 9 were grade 3. These cysts were occasionally 
symptomatic, in some cases associated with invasion into 
adjacent tissues, and developed between 36 and 910 days 
(median 230 days) after starting crizotinib. Renal cysts 
were not associated with clinically relevant changes in 
renal function.
Shifts in clinical laboratory test values from grade 2 or 
less at baseline to grade 3 or 4 postbaseline are shown 
in table 4 in the online Supplementary file 1). Among 
haematological laboratory tests, the most frequent of 
these shifts were lymphopenia (20%) and neutropenia 
(15%). Among clinical laboratory chemistries, the most 
frequent were hypophosphatemia (12%) and increased 
ALT (10%).
Permanent discontinuation of crizotinib due to TRAE 
occurred in 60 patients (6%); the most frequent TRAE 
associated with permanent treatment discontinuation 
was ILD (n=13; see table 5 in the online Supplementary 
ORR by patient characteristics*
Central ALK-testing (n=908) Local ALK-testing (n=158)
n/N** % 95% CI† n/N** % 95% CI†
  1 304/541 56 52 to 60 35/94 37 28 to 48
  2 52/125 42 33 to 51 11/18 61 36 to 83
  3 8/28 29 13 to 49 3/8 38 9 to 76
Smoking status
  Never 334/612 55 51 to 59 44/90 49 38 to 60
  Current 22/37 60 42 to 75 1/6 17 0.4 to 64
  Former 135/259 52 46 to 58 19/62 31 20 to 44
*ORR, DCR, duration of response and time to first response were analyzed in the response1evaluable population (central1testing subgroup) 
and in the response1evaluablepopulation (local1testing subgroup) (note: numbers of patients in these subgroups were the same as in the 
as1treated population).
†Calculated using the exact method based on the F distribution.
‡Based onBrookmeyer and Crowley method. 
§Range.
¶Calculated using the normal approximation to the log transformed cumulative hazard rate . 
**Number with response/total number with patient characteristic.
††Two patients received only adjuvant treatment, but had disease progression within 6 months after adjuvant treatment and were considered 
eligible for the study.
‡‡At baseline.
ALK, anaplastic lymphoma kinase; CI,confidence interval;DCR, disease-control rate (% complete response+partial response+stable disease); 
ECOG PS, Eastern Cooperative Oncology Group performance status; ORR, objective response rate; OS, overall survival; PFS, progression-
free survival.
Table 2 Continued 
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file 1). TRAEs most commonly associated with dose 
reductions were elevated transaminases (5%), neutro-
penia (4%) and fatigue (2%). The most frequent TRAEs 
associated with dosing interruptions were neutropenia 
(11%), elevated transaminases (5%), vomiting (4%) and 
nausea (4%). A total of 119 patients (11%) experienced 
treatment-related serious adverse events, each of which 
occurred in less than 2% of patients (see table 6 in the 
online Supplementary file 1). At data cut-off, 709 patients 
(67%) had died (any causality) during the study, of which 
235 patients died ≤28 days after the last dose of crizotinib; 
disease progression (n=640) was the most common cause 
of death. Fifteen patients died due to TRAEs: ILD in four 
patients, pneumonia and death in three patients each, 
hepatotoxicity in two patients and dyspnoea, pulmonary 
embolism and lung infection in one patient each (see 
table 7 in the online Supplementary file 1).
Patient-reported outcomes
In the PRO-evaluable population (n=976), mean change 
from baseline in patient-reported EORTC QLQ-C30 
global QOL scores showed a statistically significant 
(95% CI excluded 0) and clinically meaningful improve-
ment (≥10 point)8 over Cycles 3–14 (figure 2), maintained 
through Cycles 2 and 15–30. The majority of patients had 
improved (43%) or stable (39%) scores in global QOL 
over the course of treatment (see table 8 in the online 
Supplementary file 1). Of the symptoms included on the 
QLQ-C30 scale, those for which the highest proportion 
(≥40%) of patients experienced an improvement from 
baseline were pain (48%), fatigue (46%), insomnia (43%) 
and dyspnoea (42%); constipation (44%) and diarrhoea 
(44%) were the symptoms for which the highest propor-
tion (≥40%) of patients experienced worsening from 
baseline (see table 8 in the online Supplementary file 1). 
Symptoms included on the QLQ-LC13 scale that had the 
highest proportion (≥40%) of patients improved from 
baseline were coughing (51%), dyspnoea (41%) and 
pain in other parts (41%; see table 8 in the online Supple-
mentary file 1). A statistically significant improvement 
in health status, as measured by EQ-5D visual analogue 
Figure 1 Kaplan-Meier estimates of (A) progression-free survival and (B) overall survival (as-treated population). 
ALK=anaplastic lymphoma kinase.
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scale scores, was observed from Cycle 2 and maintained 
through Cycle 30.
dIscussIon
The results of PROFILE 1005 are consistent with previous 
reports for the clinical benefit of crizotinib with an ORR of 
54% demonstrated in a large population of patients with 
previously treated advanced ALK-positive NSCLC deter-
mined by break-apart FISH in a central laboratory. This 
ORR is largely in line with that in the single-arm PROFILE 
1001 trial (61%) and the crizotinib arm of the phase 3 
PROFILE 1007 trial in previously treated patients (65%) 
Table 3 Treatment-related adverse events (as-treated population, n=1066)
Event, n (%) Any grade
Maximum CTCAE
Grade 3 Grade 4
Any AE 1022 (96) 345 (32) 68 (6)
Adverse events in≥10% of patients
  Vision disorder† 615 (58) 1 (0.1) 0
  Nausea 547 (51) 17 (2) 0
  Diarrhoea 499 (47) 12 (1) 0
  Vomiting 496 (47) 11 (1) 0
  Oedema 409 (38) 15 (1) 0
  Constipation 369 (35) 2 (0.2) 0
  Elevated transaminases† 321 (30) 69 (7) 13 (1)
  Neutropenia† 226 (21) 109 (10) 28 (3)
  Fatigue 225 (21) 27 (3) 0
  Decreased appetite 224 (21) 6 (0.6) 1 (0.1)
  Dysgeusia 206 (19) 0 0
  Leucopenia† 165 (16) 32 (3) 1 (0.1)
  Dizziness† 161 (15) 2 (0.2) 0
  Neuropathy† 137 (13) 5 (0.5) 0
  Abdominal pain† 134 (13) 2 (0.2) 0
  Bradycardia† 112 (11) 3 (0.3) 0
Other adverse events of special interest<10% frequency*
  QT prolongation 37 (4) 12 (1) 0
  Renal cysts† 30 (3) 9 (0.8) 0
  Interstitial lung disease† 25 (2) 4 (0.4) 2 (0.2)
  Hepatotoxicity† 21 (2) 6 (0.6) 4 (0.4)
*AEs of special interest for crizotinib were predefined based on their clinical significance or frequency of observation in previous clinical studies and potential 
attribution to treatment with crizotinib.
†Certain preferred terms were in aggregate using clustered terms, because the frequency of certain medical concepts or conditions may have been 
underestimated by reliance on single Medical Dictionary for Regulatory Activities (MedDRA) preferred terms. MedDRA Preferred Terms within each clustered 
term that were actually reported are marked with an asterisk: Abdominal pain (Abdominal discomfort* or Abdominal pain* or Abdominal pain lower* or 
Abdominal pain upper* or Abdominal tenderness*); Bradycardia (or Bradycardia* or Heart rate decreased* or Sinus arrest or Sinus bradycardia*); Dizziness 
(Balance disorder* or Dizziness* or Dizziness exertional or Dizziness postural* or Presyncope*); Elevated transaminases (Alanine aminotransferase or Alanine 
aminotransferase abnormal* or Alanine aminotransferase increased* or Aspartate aminotransferase or Aspartate aminotransferase abnormal* or Aspartate 
aminotransferase increased* or Gamma-glutamyltransferase abnormal or Gamma-glutamyltransferase increased* or Hepatic enzyme abnormal or Hepatic 
enzyme increased* or Hepatic function abnormal* or Hypertransaminasemia or Liver function test abnormal or Transaminases or Transaminases abnormal 
or Transaminases increased*); Hepatotoxicity (Acute hepatic failure or Cholestatic liver injury or Coma hepatic or Drug-induced liver injury* or Hepatic 
encephalopathy or Hepatic failure* or Hepatic necrosis or Hepatic steatosis* or Hepatitis fulminant or Hepatocellular injury* or Hepatorenal failure or Hepatorenal 
syndrome or Hepatotoxicity* or Liver disorder* or Liver injury* or Mixed liver injury or Subacute hepatic failure); Interstitial lung disease (Acute interstitial 
pneumonitis or Acute lung injury or Acute respiratory distress syndrome* or Alveolitis* or Alveolitis allergic or Alveolitis necrotising or Diffuse alveolar damage or 
Eosinophilic pneumonia or Eosinophilic pneumonia acute or Idiopathic pulmonary fibrosis or Interstitial lung disease* or Pneumonitis* or Pulmonary toxicity); (* or 
White blood cell count decreased*); Neuropathy (Acute polyneuropathy or Amyotrophy or Areflexia or Autoimmune neuropathy or Autonomic failure syndrome or 
Autonomic neuropathy or Axonal neuropathy or Biopsy peripheral nerve abnormal or Burning feet syndrome or Burning sensation* or Decreased vibratory sense 
or Demyelinating polyneuropathy or Dysaesthesia* or Electromyogram abnormal or Formication* or Gait disturbance* or Genital hypoaesthesia or Guillain-Barre 
syndrome or Hyperaesthesia* or Hypoaesthesia* or Hyporeflexia or Hypotonia* or Ischaemic neuropathy or Loss of proprioception or Miller Fisher syndrome or 
Mononeuritis or Mononeuropathy or Mononeuropathy multiplex or Motor dysfunction* or Multifocal motor neuropathy or Muscle atrophy* or Muscular weakness* 
or Myelopathy or Nerve conduction studies abnormal or Nerve degeneration or Neuralgia* or Neuritis* or Neuromuscular toxicity or Neuromyopathy or Neuropathy 
peripheral* or Neuropathy vitamin B6 deficiency or Neurotoxicity* or Paraesthesia* or Peripheral motor neuropathy* or Peripheral nerve lesion or Peripheral nerve 
palsy or Peripheral nervous system function test abnormal or Peripheral sensorimotor neuropathy* or Peripheral sensory neuropathy* or Peroneal muscular 
atrophy or Peroneal nerve palsy* or Phrenic nerve paralysis or Polyneuropathy* or Polyneuropathy chronic or Polyneuropathy idiopathic progressive or Radiation 
neuropathy or Sensorimotor disorder or Sensory disturbance* or Sensory loss or Skin burning sensation* or Temperature perception test decreased or Tinel’s 
sign or Toxic neuropathy* or Ulnar neuritis); Neutropenia (Febrile neutropenia* or Neutropenia* or Neutrophil count decreased*); Renal cyst (Renal abscess* or 
Renal cyst* or Renal cyst excision or Renal cyst * or Renal cyst infection* or Renal cyst ruptured); Vision disorder (Chromatopsia or Diplopia* or Halo vision* or 
Photophobia* or Photopsia* or Vision blurred* or Visual acuity reduced* or Visual brightness or Visual impairment* or Visual perseveration* or Vitreous floaters*).
CTCAE, common terminology criteria for adverse events.
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but, as would be expected, less than in the crizotinib arm of 
the first-line PROFILE 1014 trial (74%).2 5 6 In the present 
study, patients were heavily pretreated, with 72% having 
received ≥2 prior lines of treatment for metastatic disease, 
and responses were required to be confirmed, while the 
designs of the randomised PROFILE 1007 and 1014 
studies did not require confirmation of tumour response. 
Tumour responses in the central-testing subgroup were 
rapid (median time to response, 6.1 weeks), consistent 
with the time of the first scheduled postbaseline tumour 
assessment and durable (median duration of response, 
11.8 months).2 5 Median PFS was 8.4 months, consistent 
with previous reports.2 5
The local ALK testing subgroup (n=158; ORR 41%, 
95% CI 33 to 49) included patients with ALK-positive 
tumours by local testing only and excluded concordant 
cases also ALK positive by central testing (see table 1 in 
the online Supplementary file 1). The higher response 
rate obtained in patients with ALK-positive tumours by 
two independent tests, local and central (n=163; ORR 
57%, 95% CI 49 to 65), may possibly be attributed to a 
lower false positive rate as compared with patients with 
ALK positive tumours by a single local test.
Crizotinib had a side effect profile with AEs that were 
generally tolerable and manageable by dosing interrup-
tion, dose reduction and/or standard medical therapy as 
there was a low frequency of permanent treatment discon-
tinuations associated with TRAEs. Most TRAEs were 
mild or moderate in severity. The most common TRAEs 
were visual and gastrointestinal in nature consistent with 
previous reports.2 5 6 Patient-reported visual events were 
transient, with minimal impact on daily activities, also as 
previously reported.2 5 9
The frequencies of hepatotoxicity, ILD and QTc 
prolongation were in line with previous reports5 6: 
treatment-related ILD of ≥grade 3 occurred in 1.0% of 
patients, no grade 4 ECG QTc prolongation was reported 
and bradycardia, mainly ≤grade 2, occurred in ~10% of 
patients in this study. Although renal imaging was not 
mandatory, renal cyst development10 was reported in 3% 
of patients and was not associated with clinically relevant 
changes in renal function.
While the large cohort of patients in PROFILE 1005 
enables more precise characterisation of the incidence 
of clinically important AEs identified in prior studies and 
in case reports,5 6 10 the TRAEs observed were similar to 
those seen in the preliminary results on which the initial 
approval of crizotinib was based, showing that smaller 
number of patients allowed the safety profile of crizotinib 
to be well characterised.
Symptom burden in patients with advanced lung cancer 
is usually high with a negative impact on QOL.11 12 The 
PRO data reported herein demonstrated clinically mean-
ingful improvements in key lung cancer symptoms and 
global QOL.
In conclusion, this study, the largest to date for any 
ALK inhibitor, supports the clinical efficacy and safety 
profile of crizotinib in patients with previously treated 
ALK-positive NSCLC. No new safety concerns were 
identified and AE frequencies were similar to, and 
consistent with, those reported in previous trials.
The results of this study strengthen the evidence base for 
crizotinib as the standard of care for ALK-positive NSCLC.
Figure 2 Mean change from baseline in patient-reported European Organisation for the Research and Treatment of Cancer 
QLQ-C30 global quality of life (patient-reported outcome-evaluable population).
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